热烈欢迎同学们报考本实验室！
刘志清 博士，教授，山东省泰山学者青年专家
中国海洋大学“青年英才工程”第一层次特聘教授
E-mail: liuzhiqing@ouc.edu.cn
Tel: 0532-82031503
主要研究方向及成果：
药物化学、天然药物化学、药理学
主要研究方向：分子靶向的海洋药物先导物发现、海洋天然产物全合成及结构修饰、活性评价及机制研究。已发表SCI论文30余篇，其中第一作者、通讯作者发表SCI文章19篇；申请国内外发明专利9项，获授权6项（美国授权5项、中国授权1项）；获得美国克罗恩病和炎性肠病基金会的Research Fellowship Award资助；参编两部著作章节；多次受邀为Journal of Medicinal Chemistry等杂志审稿人。
教育背景/Educaion：
B.Sc. 山东师范大学制药工程系 (2005-2009)
Ph. D. 中科院上海药物研究所药物化学(2009-2014)
工作经历/Work Experience：
Postdoc 美国得克萨斯大学医学分部药理与毒理系 (2014.06-2019.08)
Professor 中国海洋大学进化所&医药学院双聘 (2019.9至今)
研究兴趣/Research Interests:
1). Marine natural products: divergent total synthesis and utilization of privileged scaffold.
2). Design, synthesis and biological evaluations of small molecules as chemical probes or lead compounds for cancer, inflammations, infectious disease, CNS disorders and other human diseases.
承担项目/Grants:
1) 国家自然科学基金面上项目（74.5 万元，在研，主持）
2) 山东省泰山学者青年专家（75 万元，在研，主持）
3) 中央高校基本科研业务费（50万元，在研，主持）
4) 中国海洋大学科研启动经费（80万元，在研，主持）
5) Research Fellowship Award from Crohn’s & Colitis Foundation of America（17.5 万美元，结题，主持）
代表性论著/Selected Publication:
1) Maimaitiming M.; Lv L.; Zhang X.; Xia S.; Li X.; Wang P. *; Liu Z. *; Wang C-Y*. Semi- Synthesis and Biological Evaluation of 25(R)-26-Acetoxy-3β,5α-Dihydroxycholest-6-One. Marine Drugs. 2023; 21(3):191.
2) Li, H.#; Ouyang, S.#; Zhang, Y.; Peng, K.; Fang, W.; Liu, Z.*; Wang, C.*; Zhang, X.*; Wang, Y.* Structural Optimization of Imidazo[1, 2-a]pyridine Derivatives for the Treatment of Gastric Cancer via STAT3 Signaling Pathway. Eur. J. Med. Chem., 2022, 244:114858.
3) Li, R.#; Zhou, Y.#; Zhang, X.; Yang, L.; Liu, J.; Wightman, S. M.; Lv, L.; Liu, Z.*; Wang, C.*; Zhao, C*. Identification of Marine Natural Product Pretrichodermamide B as a STAT3 Inhibitor for Efficient Anticancer Therapy. Mar. Life Sci. Technol., 2022, 5, 94-101.
4) Li, H.#; Maimaitiming, M.#; Zhou, Y.; Li, H.; Wang, P.; Liu, Y.; Schaberle, T. F.; Liu, Z.*; Wang, C.* Discovery of Marine Natural Products as Promising Antibiotics against Pseudomonas aeruginosa. Mar. Drugs, 2022, 20, 192.
5) Liu, Z.#; Li, Y.#; Chen, H.; Lai, H. T.; Wang, P.; Wu, S. Y.; Wold, E. A.; Leonard, P. G.; Joseph, S.; Hu, H.; Chiang, C. M.; Brasier, A. R.*; Tian, B.*; Zhou, J.* Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site. J. Med. Chem.,2022, 65,3, 2388-2408.
6) Liu, Z.*, Wang, P., Wold, E.A., Song, Q., Zhao, C., Wang, C.* and Zhou, J.* Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer. J. Med. Chem.,2021, 64 (8), 4257-4288.
7) Liu, Z.; Chen, H.; Wang, P.; Li, Y.; Wold, E. A.; Leonard, P. G.; Joseph, S.; Brasier, A. R.; Tian, B.; Zhou, J. Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation. J. Med. Chem., 2020, 63, 5242-5256.
8) Niu, Q.#; Liu, Z.#; Alamer, E.; Fan, X.; Chen, H.; Endsley, J.; Gelman, B. B.; Tian, B.; Kim, J. H.; Michael, N. L.; Robb, M. L.; Ananworanich, J.; Zhou, J.; Hu, H. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. J. Clin. Invest. 2019, 129, 3361-3373. (#co-first author)
9) Liu, Z.; Tian, B.; Chen, H.; Wang, P.; Brasier, A. R.; Zhou, J. Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. Eur. J. Med. Chem. 2018, 151, 450-461.
10) Tian, B.#; Liu, Z.#; Yang, J.; Sun, H.; Zhao, Y.; Wakamiya, M.; Chen, H.; Rytting, E.; Zhou, J.; Brasier, A. R. Selective Antagonists of the Bronchiolar Epithelial NF-κB-Bromodomain-Containing Protein 4 Pathway in Viral-Induced Airway Inflammation. Cell Rep. 2018, 23, 1138-1151. (#co-first author)
代表性论著/Selected Publication:
1) Laezza, F., Zhou J., Liu, Z., Syed, A. Fine-tune modulators of neuronal excitability for neuropsychiatric disorders. US10889543B2. （2021.01.12授权）
2) Zhou, J., Brasier, A. R., Tian, B., Liu, Z., Chen, H., Rytting, E. Inhibitors of bromodomain-containing protein 4 (BRD4).US11117865B2. （2021.09.14授权）
3) Hu, H., Zhou, J., Liu, Z., Fan, X. EPAC1 activators as HIV latency reversal agents (LRAs). US10633363B2. （2020.04.28授权）
4) Zhou, J., Liu, Z., Ye, N., Mei F., Cheng, X. EPAC Antagonists. US11124489B2.（2021.09.21授权）
5) Hu, H.; Zhou, J.; Liu, Z. Novel small molecule BRD4 modulators for HIV epigenetic regulation. US 10975059B2.（2021.04.13授权）
6) 王长云，刘志清，杨金波，赵晨阳，王平原，周月，李锐，张心心，杨路佳。二酮哌嗪类天然产物及衍生物的应用、制备与所得衍生物，ZL202210076797.8 （2023.01.11授权）
